| Literature DB >> 31645551 |
Hao Chung The1, Christine Boinett1,2, Duy Pham Thanh1, Claire Jenkins3, Francois-Xavier Weill4, Benjamin P Howden5, Mary Valcanis5, Niall De Lappe6, Martin Cormican7, Sonam Wangchuk8, Ladaporn Bodhidatta9, Carl J Mason9, To Nguyen Thi Nguyen1, Tuyen Ha Thanh1, Vinh Phat Voong1, Vu Thuy Duong1, Phu Huong Lan Nguyen1,10, Paul Turner2,11, Ryan Wick12, Pieter-Jan Ceyssens13, Guy Thwaites1,2, Kathryn E Holt12,14, Nicholas R Thomson14,15, Maia A Rabaa16,17, Stephen Baker1,2,18.
Abstract
Shigella sonnei increasingly dominates the international epidemiological landscape of shigellosis. Treatment options for S. sonnei are dwindling due to resistance to several key antimicrobials, including the fluoroquinolones. Here we analyse nearly 400 S. sonnei whole genome sequences from both endemic and non-endemic regions to delineate the evolutionary history of the recently emergent fluoroquinolone-resistant S. sonnei. We reaffirm that extant resistant organisms belong to a single clonal expansion event. Our results indicate that sequential accumulation of defining mutations (gyrA-S83L, parC-S80I, and gyrA-D87G) led to the emergence of the fluoroquinolone-resistant S. sonnei population around 2007 in South Asia. This clone was then transmitted globally, resulting in establishments in Southeast Asia and Europe. Mutation analysis suggests that the clone became dominant through enhanced adaptation to oxidative stress. Experimental evolution reveals that under fluoroquinolone exposure in vitro, resistant S. sonnei develops further intolerance to the antimicrobial while the susceptible counterpart fails to attain complete resistance.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31645551 PMCID: PMC6811581 DOI: 10.1038/s41467-019-12823-0
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Summary of sequences used to investigate the emergence of fluoroquinolone-resistant Shigella sonnei
| Country | Number of sequences | In CenAsiaIII clade | CIP resistant isolates | Study or Institute of origin | Patient group | Region of recent travel history (N) | Sequencing platform | CIP susceptibility test |
|---|---|---|---|---|---|---|---|---|
| Bhutan | 71 | 71 | 71 | Diarrhoeal disease surveillance in JDWNRH, Thimphu, Bhutan (AFRIMS) | Hospitalised children <5 years old | NA | Illumina HiSeq 2000 | Disk diffusion/E-test |
| Vietnam | 24 | 22 (−2 poor sequencing quality) | 22 | Diarrhoeal disease surveillance in HCMC, Vietnam | Hospitalised children <5 years old | NA | Illumina MiSeq | Disk diffusion |
| Thailand | 8 | 8 | 1 | Cross-sectional study of | Hospitalised children <5 years old | NA | Illumina HiSeq 2000 | Disk diffusion |
| Cambodia | 1 | 1 | 1 | Cross-sectional study of | Hospitalised children <5 years old | NA | Illumina HiSeq 2000 | Disk diffusion |
| Ireland | 20 | 20 | 16 | National | Primarily patients with recent travel history | South Asia (9), Africa (1), Europe (1), No travel (5), Unknown (4) | Illumina HiSeq 2000 | Broth microdilution |
| Australia | 85 | 77 | 46 | Microbiological Diagnostic Unit Public Health Laboratory, Melbourne, Australia | Primarily patients with recent travel history | Africa (2), America (1), Southeast Asia (12), Middle East (2), Oceania (1), South Asia (60), Unknown (4) | Illumina NextSeq | Agar dilution |
| France | 97 | 95 | 72 | French National Reference Centre for | Primarily patients with recent travel history | Africa (4) America (1) Southeast Asia (4) South Asia (88) | Illumina HiSeq 2000 | Disk diffusion |
| England | 91 | 90 | 82 | Gastrointestinal Bacteria Reference Unit, Public Health England, London, UK | Primarily patients with recent travel history | Africa (3), East Asia (1), Europe (13), Middle East (1), South Asia (73) | Illumina HiSeq 2000 | Disk diffusion |
| Global references | 14 | 11 | 0 | NA | NA | NA | Illumina HiSeq 2000 | NA |
| Total | 411 | 395 | 311 |
CIP ciprofloxacin, JDWNRH Jigme Dorji Wangchuk National Reference Hospital, AFRIMS Armed Forces Research Institute of Medical Sciences, HCMC Ho Chi Minh City
Fig. 1The phylogenetic structure of CenAsiaIII Shigella sonnei. The figure displays the maximum likelihood phylogeny of 395 S. sonnei sequences belonging to the CenAsiaIII clade. The tree is rooted on the most closely related sequence from the S. sonnei global sequencing study. The branch colour scheme indicates bootstrap support for the corresponding branch, ranging from low to high (red to black). The shading covered on the phylogeny indicates taxa harbouring quinolone resistance determining region (QRDR) mutations (see key). The orange diamond indicates the internal node leading to the major fluoroquinolone-resistant (FQr) clone. The magenta triangle denotes the position of taxon 2012–02037, which was subjected to long-read sequencing (see Methods). The rings show the associated information for each taxon, from the innermost to the outermost in the following order: (1) susceptibility testing for ciprofloxacin (black: resistance; brown: susceptible); (2) original geographical source; (3) presence of different plasmids; (4) presence of ESBL blaCTX-M genes; (5) presence of mphA. The horizontal scale bar indicates the number of nucleotide substitutions per site
Fig. 2Temporal phylogenetic reconstruction of CenAsiaIII Shigella sonnei overlaid with pseudogenes. A maximum clade credibility phylogenetic reconstruction of 144 CenAsiaIII S. sonnei is shown. Asterisks indicate posterior probability support >80% on major internal nodes. The red diamond indicates the internal node leading to the major fluoroquinolone-resistant (FQr) clone. Grey arrows designate branches on which certain quinolone resistance determining region (QRDR) mutations occurred. Lineage-defining pseudogenes and gene loss events are indicated above corresponding branches. Tip colours show the original geographical isolation regions of taxa (see key). The light orange and light yellow boxes highlight the European and Southeast Asian clonal expansions of CenAsiaIII, respectively. The dark dashed line separates the two populations (Pop1 and Pop2) in CenAsiaIII, defined by Bayesian hierarchical clustering
Fig. 3Phylogeographical inference of CenAsiaIII Shigella sonnei. Stochastic mapping was used to estimate a the number of transitions between different geographical states: Africa, Southeast/East Asia, Europe, and South Asia, with transitions between states that are less than one considered non-significant and not represented in the plot, and b the proportion of time spent in each geographical state. In both panels, boxplots summarise results of 966 successful subsamplings of the phylogeny described in Fig. 1, and stochastic mapping was performed for each with 100 simulations
Genes predicted to be under selection in the CenAsiaIII Shigella sonnei population
| Gene | No. of Na SNPs | No. of Sb SNPs | Adjusted dN/dS | Product | GOc process |
|---|---|---|---|---|---|
|
| 10 | 0 | Inf | Dynamic cytoskeleton protein | Regulation of cell shape |
|
| 8 | 0 | Inf | DNA gyrase subunit A | Response to antibiotic |
|
| 8 | 1 | 3.557 | Proline dehydrogenase | Response to oxidative stress |
|
| 7 | 0 | Inf | Serine protease | NA |
|
| 6 | 0 | Inf | Serine/threonine symporter | Amino acid transport |
|
| 5 | 0 | Inf | Hypothetical protein | NA |
|
| 5 | 0 | Inf | Dethiobiotin synthetase | Biotin biosynthesis |
|
| 5 | 0 | Inf | 2-octaprenyl-6-methoxyphenol hydroxylase | Ubiquinone biosynthesis; response to oxidative stress |
|
| 5 | 0 | Inf | DNA topoisomerase IV subunit A | Response to antibiotic |
|
| 5 | 1 | 2.22 | Membrane | NA |
|
| 5 | 1 | 2.223 | Putative transport protein MFSd | Transmembrane transport |
|
| 4 | 1 | 1.778 | Hypothetical protein | NA |
|
| 4 | 1 | 1.778 | Pyruvate flavodoxin oxidoreductase | Response to oxidative stress |
|
| 4 | 1 | 1.778 | Hydrogenase 4, component B | Oxidation-reduction |
aNon-synonymous single-nucleotide polymorphisms
bSynonymous single-nucleotide polymorphisms
cGene ontology biological process, as defined in EcoCyc for Escherichia coli K-12 MG1655
dMajor facilitator superfamily
Results of antimicrobial susceptibility and mutation analysis of experimental evolution in Shigella sonnei
| Conditiona | MIC-CIP (μg/mL) | MIC-NAL (μg/mL) | Resistance mutations | Other mutationsd | Genomic deletion |
|---|---|---|---|---|---|
| cipS-VN: D0b | 0.25 | 64 (sat) | |||
| cipS-VN: M9-A | 0.19 | 64 (sat) | |||
| cipS-VN: M9-B | 0.25 | 64 (sat) | |||
| cipS-VN: NAL-A | 0.5 | >256 | |||
| cipS-VN: NAL-B | 0.38 | >256 | |||
| cipS-VN: CIP-A | 0.38 | >256 | |||
| cipS-VN: CIP-B | 0.75 | >256 | |||
| cipR-VN: D0 | 8 | >256 | |||
| cipR-VN: M9-A | 8 | NA | |||
| cipR-VN: M9-B | 6 | NA | |||
| cipR-VN: NAL-A | 12 | NA | SSON_1790 (stop codon); | ||
| cipR-VN: NAL-B | 8 | NA | |||
| cipR-VN: CIP-A | 16 (sat) | NA | |||
| cipR-VN: CIP-B | 16 (sat) | NA | SSON_1804 (N200K) |
fs frameshift mutation
aIn all conditions, selected strains were cultured in minimal M9 medium supplemented with glucose and niacin (25 μg/mL) with the addition of: (1) M9-A/B: no antimicrobial, (2) NAL-A/B: the same concentration of nalidixic acid (256 μg/mL). (3) CIP-A/B: ciprofloxacin in concentrations of half the corresponding MIC of the respective strain (0.125 μg/mL for cipS-VN and 4 μg/mL for cipR-VN). cipS-VN indicates the use of a ciprofloxacin-sensitive S. sonnei (gyrA-S83L; Global III clade) strain and cipR-VN indicates the use of a ciprofloxacin-resistant S. sonnei (gyrA-S83L, gyrA-D87G and parC-S80I; CenAsiaIII clade) strain. (sat): satellite colonies grown inside the zone of inhibition.
bD0: initial condition on day 0.
cMutations in bold indicate those that appear to be fixed in the examined population.
dExcluding synonymous mutations, and mutations found in intergenic regions and repetitive genetic elements.